A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Reduce the Incidence, Severity and Duration of Acute Noise Induced Hearing Loss (NIHL)

Trial Profile

A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Reduce the Incidence, Severity and Duration of Acute Noise Induced Hearing Loss (NIHL)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Ebselen (Primary)
  • Indications Noise-induced hearing loss
  • Focus Therapeutic Use
  • Acronyms NIHL
  • Sponsors Sound Pharmaceuticals
  • Most Recent Events

    • 24 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top